Immusoft
Immusoft develops cell therapies that program patients’ own B cells to produce therapeutic proteins for sustained delivery. Its therapies are intended for people with rare and other diseases with significant unmet need.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2009
- Type
- Corporation Seattle business license
- Employees
- 21
- Registered name
- Immusoft Corp Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- Matthew Scholz
Is this your organization? Claim it
Immusoft to Present Positive First-in-Human Data for ISP-001 Engineered B Cell Therapy in MPS I at ASGCT 2026
Immusoft will present positive clinical data showing favorable safety, tolerability, biochemical activity, and safe re-dosing for ISP-001, the world’s first engineered autologous B cell therapy for MPS I, supporting continued adult development and planned pediatric expansion.
Immusoft explores scientific, ethical, regulatory, and practical considerations shaping pediatric cell and gene therapy clinical trial design
This article examines the scientific, ethical, regulatory, and practical factors that influence the design of pediatric cell and gene therapy (CGT) clinical trials, highlighting challenges and considerations specific to children. It aims to guide researchers and stakeholders in creating trials that balance safety, efficacy, and ethical responsibilities for pediatric populations.
Immusoft to Present World’s First Patient Treated with Engineered B Cell Therapy ISP-001 Showing Safe Re-dosing and Early Efficacy
Immusoft will present the world’s first clinical case of an engineered B cell therapy (ISP-001) treating MPS I, reporting favorable safety, the ability to safely re-dose, and early pharmacodynamic and functional improvements in treated patients.
Immusoft awarded $15 million CIRM grant to advance ISP-001 engineered B‑cell therapy for MPS I
Immusoft received a $15 million grant from the California Institute for Regenerative Medicine to expand clinical development of ISP-001, its engineered B‑cell therapy for mucopolysaccharidosis type I (MPS I). Early Phase 1/2 data show favorable safety and tolerability, successful re-dosing, and encouraging pharmacodynamic and functional signals.
Immusoft awarded $15 million CIRM grant to advance ISP-001 for MPS I after promising Phase 1/2 safety and re-dosing results
Immusoft received a $15 million grant from the California Institute for Regenerative Medicine to advance clinical development of ISP-001, its engineered B cell therapy for mucopolysaccharidosis type I, after early Phase 1/2 data showed favorable safety, tolerability, and signs of functional benefit including successful re-dosing.
Immusoft’s ISP-002 Earns FDA Rare Pediatric Disease Designation for MPS II, Enabling Potential Priority Review Voucher
Immusoft’s investigational engineered B cell therapy ISP-002 received FDA Rare Pediatric Disease designation for treating mucopolysaccharidosis type II (Hunter syndrome), making the program eligible for a Priority Review Voucher upon approval. ISP-002 is designed to use patients’ own B cells to continuously produce iduronate-2-sulfatase (IDS) as an alternative to frequent enzyme replacement infusions.
Immusoft Announces FDA Orphan Drug Designation for ISP-002, Engineered B Cell Therapy for MPS II
Immusoft received FDA Orphan Drug Designation for ISP-002, its investigational engineered B cell therapy for MPS II (Hunter syndrome), which programs patients' B cells to continuously produce the deficient enzyme IDS. The designation supports Immusoft’s broader engineered B cell platform strategy and highlights potential benefits over current enzyme replacement therapies, including sustained enzyme production and reduced treatment burden.
People
-
Sean Ainsworth Executive, Executive Officer, Director, Chief Executive Officer
-
Scott McIvor Executive, Chief Development Officer